Abstract
Herein, we aimed to describe the outcomes of patients with blood stream infections due to carbapenem-resistant Klebsiella pneumoniae (CR-Kp) who received ertapenem plus meropenem combination treatment (EMCT). A total of 53 patients with culture proven CR-Kp bacteremia treated with ertapenem + meropenem were included. The patients with secondary bacteremia due to urinary tract infection exhibited a significantly lower 1-month mortality (OMM), particularly in those with microbiological eradication and those with end-of-treatment success. Salvage EMCT resulted in 49% 1-month survival.
This is a preview of subscription content, log in via an institution to check access.
Data availability
The data that support the findings of this study are not publicly available but can be provided with request from the corresponding author, UÖ.
Code availability
None available.
References
Tamma PD, Aitken SL, Bonomo RA (2022) Infectious Diseases Society of America antimicrobial-resistant treatment guidance: gram-negative bacterial infections. Infectious Diseases Society of America 2022; Version 1.1. https://www.idsociety.org/practice-guideline/amr-guidance/. Accessed 28 April 2023
Moody RO (2021) The effect of double-carbapenem therapy on mortality rates and microbiological cure rates in patients diagnosed with carbapenem -resistant Klebsiella pneumoniae infections in comparison to monotherapy and currently used combinations of antibiotics: a meta-analysis. J Med Res Innov 5:e000243
Önal U, Sipahi OR, Pullukçu H (2020) Retrospective evaluation of the patients with urinary tract infections due to carbapenemase producing Enterobacteriaceae. J Chemother 32:15–20
Önal U, Akyol D, Mert M (2022) Carbapenem-resistant Gram-negative pathogens associated with septic shock: a review of 120cases. J Chemother 34:436–445
Yy Li, Wang J, Wang R (2020) Double-carbapenem therapy in the treatment of multidrug resistant Gram-negative bacterial infections: a systematic review and meta-analysis. BMC Infect Dis 20:408
CDC, National Healthcare Safety Network (NHSN) Patient safety component manual. (2023). https://www.cdc.gov/nhsn/pdfs/pscmanual/pcsmanual_current.pdf. Accessed 28 April 2023
Paul M, Carrara E, Retamar P (2022) European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European Society of Intensive Care Medicine). Clin Microbiol Infect 28:521–547
Social Security Institution, Health Practice Statement (2021). https://www.saglikaktuel.com/mobi/haber/saglik-uygulama-tebliginde-degisiklik-yapilmasina-dair-teblig-28-04-2021-71706.htm. Accessed 28 April 2023
Noyan A, Sipahi OR, Cilli F, Aydemir S (2022) Ceftazidime-avibactam susceptibility patterns of carbapenem-resistant Klebsiella pneumoniae and Pseudomonas aeruginosa clinical strains in tertiary care educational hospital in Turkey. Europ Conf Clin Microbiol Infect Dis P0554. https://online.eccmid.org/container-intervention-lookup.php?p=1&interv=P0554
Venugopalan V, Nogid B, Le TN (2017) Double carbapenem therapy (DCT) for bacteremia due to carbapenem-resistant Klebsiella pneumoniae (CRKP): from test tube to clinical practice. Infect Dis (Lond) 49:867–870
Souli M, Karaiskos I, Masgala A (2017) Double-carbapenem combination as salvage therapy for untreatable infections by KPC-2-producing Klebsiella pneumoniae. Eur J Clin Microbiol Infect Dis 36:1305–1315
Cprek JB, Gallagher JC (2015) Ertapenem-containing double-carbapenem therapy for treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother 60:669–673
Zarakolu P, Eser ÖK, Otlu B (2022) In-vitro activity of fosfomycin against Escherichia coli and Klebsiella pneumoniae bloodstream isolates and frequency of OXA-48, NDM, KPC, VIM, IMP types of carbapenemases in the carbapenem-resistant groups. J Chemother 34:235–240
Allander L, Vickberg K, Lagerbäck P (2022) Evaluation of in vitro activity of double-carbapenem combinations against KPC-2-, OXA-48- and NDM-producing Escherichia coli and Klebsiella pneumoniae. Antibiotics (Basel) 11:1646
Aslan AT, Kırbaş E, Sancak B (2022) A retrospective observational cohort study of the clinical epidemiology of bloodstream infections due to carbapenem-resistant Klebsiella pneumoniae in an OXA-48 endemic setting. Int J Antimicrob Agents 59:106554
Wang M, Earley M, Chen L (2022) Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study. Lancet Infect Dis 22:401–412
Author information
Authors and Affiliations
Contributions
Author UÖ and author ORS have given substantial contributions to the conception or the design of the manuscript; author UÖ, DA, AK, DB, BK, GŞ, AUÖ, CBA, MM, and SM to acquisition, analysis and interpretation of the data; and author ORS revised it critically.
Corresponding author
Ethics declarations
Ethics approval
This study was approved by the local Institutional Review Board (21-6.1 T/63 on June 25, 2021).
Consent to participate
All authors have participated to drafting the manuscript.
Consent for publication
All authors read and approved the final version of the manuscript.
Competing interests
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Önal, U., Akyol, D., Kaya, A. et al. Ertapenem plus meropenem combination treatment in carbapenem-resistant Klebsiella pneumoniae bacteremia: an analysis of 53 cases. Eur J Clin Microbiol Infect Dis 42, 1269–1273 (2023). https://doi.org/10.1007/s10096-023-04660-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10096-023-04660-3